Press Release
DYNAMX BIOADAPTOR RESTORES ROTATIONAL MOTION AND VESSEL STRESS REDUCTION IN NEW STUDY
Paper Published in Cardiovascular Revascularization Medicine Shows Innovative Coronary Artery Implant is Capable of Moving with Vessel, Unlike Conventional Stents MILPITAS, Calif. – June 1, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced print publication of a study in the latest issue of Cardiovascular Revascularization Medicine that showed that the […]
ELIXIR MEDICAL STRENGTHENS ITS COMMERCIAL CAPABILITIES WITH THE ADDITION OF AHRAM AS EXECUTIVE VICE PRESIDENT, INTERNATIONAL
MILPITAS, Calif. – March 24, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, International. Mr. Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and […]
ELIXIR MEDICAL STRENGTHENS ITS COMMERCIAL CAPABILITIES WITH THE ADDITION OF AHRAM AS EXECUTIVE VICE PRESIDENT, INTERNATIONAL
MILPITAS, Calif. – March 24, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, International. Mr. Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and the […]
ELIXIR MEDICAL COMPLETES ENROLLMENT IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
MILPITAS, Calif. – February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal […]
ELIXIR MEDICAL COMPLETES ENROLLMENT IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
MILPITAS, Calif. – February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal […]